Product image of Montalis (Montelukast) supplied by GNH India

Montalis

Active Ingredient:
Montelukast
Origin:
EU

Montalis (Montelukast)

Montelukast, the active ingredient in Montalis, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adults and children, helping to reduce airway inflammation and improve breathing control.

GNH India supplies Montalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks and regulatory compliance across EU and other markets. The company adheres to Good Distribution Practice, ensuring product integrity and timely delivery to healthcare providers worldwide.

Manufacturer / TM Owner

Zwitter Pharmaceuticals Επε

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation.

  • Asthma: improves control of persistent asthma, reduces frequency of exacerbations, and decreases need for rescue inhaler use.
  • Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergic rhinitis.
  • Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity, allowing better exercise tolerance in susceptible individuals.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and inflammatory cells. By antagonizing this receptor, it inhibits the actions of leukotriene D4 and related mediators that cause bronchoconstriction, mucus secretion, vascular permeability and eosinophilic inflammation, thereby improving airway patency and reducing allergic inflammation. The effect is dose‑dependent and contributes to long‑term control of symptoms in chronic respiratory diseases.

Side Effects

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Headache: mild to moderate headache.
  • Upper respiratory tract infection: symptoms of cold or sinusitis.
  • Cough: occasional non‑productive cough.
  • Abdominal pain: mild stomach discomfort.
  • Diarrhea: loose stools.
  • Rash: mild skin redness or itching.

Serious or Rare Side Effects

  • Neuropsychiatric events: agitation, anxiety, depression, or suicidal thoughts.
  • Allergic reactions: hives, swelling of face, lips or tongue.
  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Angioedema: rapid swelling of the face or airway.
  • Blood dyscrasias: eosinophilia or neutropenia.

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

  • Pregnancy: category B; use only if benefit outweighs potential risk.
  • Lactation: excreted in breast milk; weigh benefits against infant exposure.
  • Hepatic impairment: monitor liver function in patients with liver disease.
  • Concomitant asthma therapy: continue inhaled corticosteroids; do not substitute.
  • Neuropsychiatric monitoring: observe for mood changes or suicidal ideation.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Phenobarbital: may reduce montelukast plasma concentrations.
  • Rifampin: induces metabolism leading to decreased effectiveness.

Moderate Interactions (Monitor Closely)

  • Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric side effects.
  • Warfarin: potential alteration of anticoagulant effect; monitor INR.
  • CYP2C9 inhibitors (e.g., fluconazole): may modestly increase montelukast levels.
  • Herbal supplements (St. John’s wort): may induce metabolism, reducing drug exposure.

Frequently Asked Questions

Montalis contains the active ingredient montelukast and is prescribed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction. By targeting leukotriene pathways, it helps reduce airway inflammation, improve breathing, and lessen allergy‑related nasal symptoms.

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle and inflammatory cells. This inhibition prevents leukotriene‑mediated bronchoconstriction, mucus production, and vascular leakage, thereby easing airway narrowing and allergic inflammation.

The appropriate dose of Montalis is set by the prescribing healthcare professional based on the patient’s age, weight, disease severity, and response to therapy. Dosage adjustments are made according to clinical judgment and current treatment guidelines.

Montelukast is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Small amounts are excreted in breast milk, so a risk‑benefit assessment is required for nursing mothers.

To order Montalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montalis (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or those who prefer a once‑daily tablet, but it does not replace inhaled steroids for severe persistent asthma.

Store Montalis tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Montalis is taken orally as a tablet, usually once daily in the evening. It can be swallowed with or without food, following the dosing instructions provided by the prescriber.

Serious adverse events include neuropsychiatric reactions such as agitation, depression, anxiety, or suicidal thoughts, as well as severe allergic responses like anaphylaxis, angioedema, and liver injury. Patients should seek immediate medical attention if they experience any of these symptoms.

Montalis should be avoided in individuals with known hypersensitivity to montelukast or any component of the tablet. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT